HIV-1 Drug Resistance Among Treatment-Naive Transgenders from India.
PMID: 34652967
2021
AIDS research and human retroviruses
Abstract: Mutations M184V, A98G, K103N, G190A, and Y318F associated with resistance to nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitors were observed.
Performance of Affinity-Improved DARPin Targeting HIV Capsid Domain in Interference of Viral Progeny Production.
Discussion: For example, the M184V mutation along with thymidine analogue-associated mutations (TAMs) in HIV-1 reverse transcriptase gene increases abacavir resistance.
Prevalence and Molecular Epidemiology of Transmitted Drug Resistance and Genetic Transmission Networks Among Newly Diagnosed People Living With HIV/AIDS in a Minority Area, China.
Result: M184MI/V (0.38%) was the most prevalent NRTI-associated mutation, followed by T215F/L (0.30%).
Discussion: Although it is still debatable whether continued use of 3TC provides actual benefit, it is still lacking a fully active multitherapy in the presence of the M184V mutation, which would lead to a greater risk for virologic failure and may be related to higher TDR in newly diagnosed PLWH.
Discussion: It is reported that the M184MI/V mutation showed a high- and intermediate-level resistance to 3TC that reduces the replicative capacity of reverse transcriptase.
Discussion: Our study found that the two NRTI mutations (M184MI/V and PMID: 34795836
2021
The Pan African medical journal
Result: Besides DRMs assessed by PANDAA (K65R, M184V, K103N, Y181C and G190A), additional major DRMs to NRTI (L74I, D67N, K70E and K219R) were found in 3/120 participants (3%), as follows: L74I in combination with M184V were found in 2/120 participants (2%) and D67N +K70E+219R together with M184V occurred in 1 participant (1%).
Result: Pre-treatment drug resistance (K65R, M184V,
Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.
Abstract: Among NRTI resistance mutations, M184V (73.2%), K219Q (63.4%) and T215 (56.1%) complex were the most mutated positions, while the most common NNRTI resistance mutations were K103N (24.4%), K101E, P225H and V108I 7.5% each.
Result: Among NRTI resistance mutations, M184V (73.2%), and K219Q, (63.4%) were the most common resistance mutations detected from viraemic subjects, respectively.
Table: M184V
Discussion: A recent global research conducted in an attempt to find a point of care genotypic resistance test to detect HIV-1 drug resistance
[HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018].
PMID: 34814456
2021
Zhonghua liu xing bing xue za zhi
Abstract: The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%).
HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020.
Result: The most commonly observed DRMs were K103NS (24.1%) and M184VI (23.3%) in RT.
Discussion: Taking this into consideration, most ADR cases observed in the present study could still be associated with failures to offer efavirenz-based first-line regimens in persons who had not yet switched to INSTI-based options, which is also consistent with the high frequency of K103NS and M184VI observed in persons with ADR.
[Prevalence of transmitted drug resistance in HIV-infected treatment-naive patients in Chile].
Abstract: The mutations in reverse transcriptase were M41L, L210W, D67N, K70E, M184V, K103N (6.36%, 95% CI 3.5-10.4), G190A, E138A, K101E, and I84V in protease.
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Abstract: The most prevalent Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations were M184V/I (67.3%), K219/Q/E (22.6%) and K65R (21.1%).
Discussion: However, M184V/I (67 (55.8%), p = 0.015), Y188L (9 (100%), p = 0.008) and TAMs (44 (51.8%), p = 0.011) were noted more in subtype A, but the number of occurrence of these mutations could not affect the overall association, therefore the study finds these individual mutation observations statistically irrelevant.
Discussion: The high prevalence of M184V might be attributed to the continued usage of lamivudine as a backbone in all regimens in Uganda and all over sub-Saharan since the presence of this mutation reduces the viral replicative fitness and increases susceptibil
Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimi din-4(3H)-ones as potential HIV-1 inhibitors.
HIV mutation literature information.
PMID: 
2021
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT